Clinical Interventions in Aging

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Aging in Otolaryngology – Head and Neck Surgery" in Clinical Interventions in Aging.

Demographic shifts toward an increasingly aged global population demand heightened attention to age-related pathophysiology within otorhinolaryngology–head and neck surgery. This Article Collection explores the multifaceted impact of senescence on audiovestibular, sinonasal, laryngopharyngeal, and head and neck surgical disciplines. Conditions such as presbycusis, presbystasis, presbylarynx, presbyphagia, and age-related immunosenescence present distinctive diagnostic and therapeutic challenges. Molecular mechanisms underlying age-related deterioration - including oxidative stress pathways, mitochondrial dysfunction, and altered inflammatory cascades - warrant particular consideration.

Moreover, geriatric frailty and polypharmacy significantly influence perioperative risk stratification and postoperative rehabilitation. The intersection of gerontology and otolaryngology–head and neck surgery requires innovation in clinical approaches, including targeted interventions that address the unique physiological, cognitive, and functional considerations of the older patient population within this surgical domain.

The significance of age-focused otolaryngology is multidimensional. Demographically, individuals over 65 years will constitute an increasing proportion of the global population in the coming decades, accompanied by a growing incidence of age-related otolaryngologic conditions. Clinically, senescent changes in head and neck structures directly affect speech, voice, swallowing, breathing, hearing, and balance - fundamental aspects of human function. Economically, appropriately tailored interventions can reduce healthcare expenditures through fewer complications and hospitalizations. Scientifically, advancing our understanding of the molecular basis of otolaryngologic aging contributes to broader gerontological paradigms. Ethically, addressing these age-related conditions supports dignity, autonomy, and quality of life, representing both a clinical priority and a moral imperative.

We invite systematic reviews, state-of-the-art reviews, and original research articles that examine the impact of aging across the full spectrum of otolaryngology–head and neck surgery. Submissions may address clinical, translational, or basic science aspects in the following areas, including but not limited to:

• Laryngology: age-related voice disorders (presbylarynx), dysphagia (presbyphagia), laryngeal neuromuscular degeneration, and innovations in diagnosis and voice therapy or surgical interventions for older adults
• Head and Neck Surgery: surgical outcomes, risk stratification, reconstructive techniques, and perioperative management in geriatric patients undergoing procedures for benign or malignant conditions
• Oncology: epidemiology, tumor biology, and treatment responses of head and neck cancers in older adults
• Otology and Neuro-otology: presbycusis, balance disorders (presbystasis), cochlear implantation in the elderly, age-related central auditory processing, and vestibular rehabilitation strategies
• Rhinology: chronic rhinosinusitis, olfactory dysfunction, age-associated mucosal changes, and surgical or medical management tailored to geriatric physiology

A focus will be done for innovation in medical and surgical fields of otolaryngology in older adults.

Please submit your manuscript on our website, quoting the promo code A944F to indicate that your submission is for consideration in this Article Collection.

Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 31 July 2026.

Guest Advisors:

Jerome R. Lechien, University of Mons, Belgium

[email protected]

Jerome R. Lechien is professor and chair of surgery in University of Mons, Belgium. He is consultant in robotic and laryngeal surgery in Foch Hospital, Paris, France and member of several scientific societies, including American College of Surgery (ACS), ABEA, CEORL, UEP, and ELS.

Lise Sogalow, University of Mons, Belgium

[email protected]

Dr. Sogalow is medical doctor and PhD candidate in Artificial Intelligence in University of Mons, Belgium.

Antonino Maniaci, University of Enna

[email protected]

Prof. Dr. Antonino Maniaci, born in Messina in 1989, is an Associate Professor of Otolaryngology at the University of Enna Kore, Italy, specializing in rhinology, head and neck oncology, and sleep apnea disorders. He holds a Ph.D. in Biomedical Sciences and has completed advanced training and fellowships in prestigious institutions across Europe, including Marseille and Forlì. With over 287 scientific publications and an H-index of 27, his research focuses on inflammatory and oncological diseases, genetic alterations, and innovative treatments in otolaryngology. He serves as European Secretary of YoIFOS and is actively involved in coordinating international research projects, conferences, and fellowships. Prof. Maniaci has received numerous awards, is a member of editorial boards of high-impact journals, and frequently speaks at international conferences.

View all papers in this article collection

We are pleased to announce a new Article Collection in Clinical Interventions in Aging, titled: Biomarker-Guided Clinical Interventions in Geriatric Heart Failure: From Phenotyping to Practice.

Heart failure (HF) affects over 64 million people worldwide and disproportionately burdens adults aged 65 and above, in whom clinical presentation, comorbidity burden, and physiological reserve differ markedly from younger patients. In this population, guideline-directed medical therapies — including renin-angiotensin-aldosterone system inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — produce variable effects on biomarkers of inflammation, neurohormonal activation, and cardiorenal stress, with evidence specific to older adults remaining limited. Understanding how clinical interventions modify these biological signals, whether changes in these biomarkers predict downstream outcomes such as mortality and HF hospitalization, and how biomarker-informed phenotyping can personalize therapeutic decision-making, represents one of the most pressing challenges in current geriatric cardiology.

The aging HF population is not homogeneous. Older adults with HF span a spectrum from the relatively fit patient with isolated left ventricular dysfunction to the frail, multimorbid individual with cardiorenal-hepatic syndrome and limited tolerance for aggressive pharmacotherapy. Emerging evidence indicates that circulating inflammatory markers (interleukin-6, CRP, GDF-15), cardiorenal biomarkers (cystatin C, NGAL), and neurohormonal indicators respond differentially to pharmacological, device-based, and rehabilitative interventions depending on the patient’s phenotypic subtype. Identifying which interventions most effectively normalize these biomarkers — and which patient subgroups benefit most — has direct implications for risk stratification and treatment personalization in older adults.

This Article Collection invites original research, systematic reviews, and narrative reviews examining how clinical interventions in older adults with HF influence biomarker profiles, phenotypic trajectories, and patient outcomes. Relevant subtopics include: the effects of pharmacological therapies (SGLT2 inhibitors, ARNIs, mineralocorticoid receptor antagonists) on inflammatory, neurohormonal, and cardiorenal biomarkers in patients aged 65 and above; the impact of device-based therapies (ICD, CRT, LVAD) and structured cardiac rehabilitation on biomarker levels and phenotypic classification in geriatric HF cohorts; biomarker-guided treatment titration and serial monitoring strategies in older adults with acute or chronic HF; machine learning and phenotyping approaches that identify which patient subgroups derive the greatest benefit from specific interventions; sex-, ethnicity-, and geography-specific variation in biomarker responses to clinical interventions; and real-world multicentred data on intervention outcomes in older adults with HF, including frail and multimorbid subgroups. Studies from diverse geographic regions, including Asia, Europe, and the Americas, are particularly encouraged.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer review if they can pass the desk assessments as part of our standard editorial process; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please submit your manuscript on our website. Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 31 January 2027.

Please contact Catherine Teng at [email protected] with any queries and discount codes regarding this Article Collection.

Guest advisors

Dr Thien Tan Tri Tai Truyen, Cedars Sinai Medical Center

[email protected]

Dr. Truyen is a cardiovascular researcher at the Smidt Heart Institute, Cedars-Sinai Medical Center, working within the Center for Cardiac Arrest Prevention. His research focus sudden cardiac death, geriatric heart failure phenotyping, and machine learning-based risk stratification, with publications in Circulation: Arrhythmia and Electrophysiology, JACC: Advances, and JAHA. He serves as an Academic Editor for Frontiers in Medicine and PLOS ONE, and completed advanced training through Harvard Medical School's Global Clinical Scholars Research Training Program. He is also a current fellow of American College of Cardiology.

Dr Loc Vu, School of Medicine, Tan Tao University

[email protected]

Physician-scientist specializing in cardiovascular research and coronary hemodynamics. I am actively engaged in clinical training and research, with work recognized internationally, including multiple American Heart Association – Paul Dudley White International Scholar Awards (2021–2024), the top abstracts score at AHA 2022, and awards from the European Society of Cardiology. I also serve as a Social Media Ambassador for the Cardiovascular Research Foundation (CVRF, Korea) and as the Founder and Managing Director of the Doctor Plus platform, a physician-led initiative with over 130,000 followers.

View all papers in this article collection